Ms. Sonia Bednarowski

RAPT Therapeutics, Inc.

We note your response to comment 4. Please remove conclusory statements from your prospectus summary regarding the results of your preclinical studies and instead please provide a balanced summary of the studies, including the range of results observed, a summary of how the study was conducted and a discussion that results in preclinical studies do not necessarily predict the results in clinical studies. For example, on page 2, you state that FLX475 was shown to bind to CCR4 and inhibit recruitment of Treg into tumors without affecting healthy tissue, increase the number of CD8+ effector T cells in the tumor, improve tumor control and lead to tumor reduction or eradication, and on page 4, you state that your preclinical studies have demonstrated the ability to restore T cell proliferation and function in nutrient-deprived conditions, to overcome immune suppression induced by myeloid-derived suppressor cells, and to elicit antitumor responses in animal models.

We note your response to comment 6. Please revise your disclosure here and throughout your prospectus to remove statements that imply an expectation of regulatory approval, including claims regarding the safety and efficacy of your product candidates, as these statements are inappropriate given the stage of development. For example, on page 2, you compare RPT193 to currently marketed injectable biologics and state that RPT193 is as safe and effective as these current standard of care, and on page 113, you provide a chart that addresses the safety and efficacy of RPT193 and compares this product candidate to the current standard of care and emerging clinical-stage drug candidates.

We note your response to comment 1. In this section and throughout the prospectus, please remove comparisons of your drug candidates to other product candidates, products and treatments. For example, on page 2, you state that your approach is designed to avoid depleting immune cells and broadly suppressing the immune system, “a side effect experienced with other approaches, “ and you state that your product is designed to avoid adverse safety affect and discuss the adverse safety events that have been observed in other products and treatments. Similarly, on page 3, you compare your preclinical pharmacology and toxicology results for RPT193 to existing and emerging clinical stage drug candidates.

We note your disclosure on pages 59 and 171 that the exclusive forum provision in the amended and restated certificate of incorporation that will be in effect upon the closing of this offering does not apply to claims brought under the Exchange Act. However, we note that your form of amended and restated bylaws, filed as Exhibit 3.6, contains an exclusive forum provision is Section 48 of Article XV that is inconsistent with your disclosure and Section VII of your form of amended and restated certificate of incorporation filed as Exhibit 3.4. Please revise your disclosure in the prospectus to discuss the provision in the bylaws and revise Section 48 of Article XV so that it is

We note your response to comment 7. Please revise here and throughout the prospectus to remove conclusory statements regarding the results of your preclinical and clinical studies. Instead, when disclosing observed results of your preclinical and clinical trials, please disclose the range of results observed, how the studies and tests were conducted, the endpoints of the clinical trials and whether the results were statistically significant. For example on page 85, you state that FLX475 “selectively inhibits the migration of immunosuppressive regulatory T cells (Treg) into tumors,” and, on page 87, you state that FLX475 “blocks the migration of Treg specifically into tumors, but not healthy tissues, without depleting Treg throughout the body.”

We note your disclosure that the highest level of inhibition of Treg migration and increase in CD8+ effector cells was observed in your preclinical studies at 10 mg/kg given once daily, which achieved concentrations that inhibit 90% of in vitro Treg migration (“IC90”) throughout the dosing period. Please disclose whether all seven mice in each experiment received the same dose and the range of results observed. Similarly, for each preclinical study conducted, including the preclinical studies for RPT193 and your other product candidates, disclose the range of results observed, and, if you used a p-value in the study, disclose the p-value used and whether the results were statistically significant. For example, we note your disclosure that you observed in four independent experiments with five mice per experimental arm that the treatment with checkpoint inhibitors led to a statistically significant increase in the expression of CCR4 ligands but you do not disclose the p-value used to determine statistical significance or the range of results observed.

We note your response to comment 12. Please disclose the key terms of your clinical trial collaboration and supply agreement with Merck, including the term of the agreement, any cost sharing of the clinical trials and provisions related to the ownership of the materials and data used and generated in the clinical trials as well as any new intellectual property developed pursuant to the agreement.

Brian Wong, RAPT Therapeutics, Inc.